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Abstract
Background: Women living in rural and under-resourced Appalachian Kentucky may
experience delays in receiving cancer treatment yet such delays have not been
systematically evaluated. In this analysis, we hypothesize that women diagnosed with
breast cancer who live in Appalachian Kentucky would be more likely to have a
treatment delay compared to those living in other Kentucky regions and adjusting for
individual measures of socioeconomic status.
Methods: In this cohort study, women included in the Kentucky Cancer Registry with a
diagnosis of an incident, primary breast cancer in the prior 12 months were interviewed
by phone (n=1,245; response rate 26.9%). Cox proportional hazards regression analysis
was used to estimate rates of any treatment initiation and rates of specific types of first
treatment of Appalachian residence relative to non-Appalachian residence after a breast
cancer diagnosis.
Results: In contrast to our hypothesis, Appalachian women received any first cancer
treatment sooner than non-Appalachian women after adjusting for age and stage (adjusted
hazard ratio= 1.14; p=0.04). When additionally adjusting for income and health
insurance, this association was no longer statistically significant (adjusted hazard
ratio=1.11; p=0.14). Among women diagnosed at an earlier stage (n=899), Appalachian
residents received first treatment (primarily surgery) sooner than Non-Appalachian
women (p=0.05) and among those diagnosed at a later stage (n=346), Appalachian
residence received radiation sooner than non-Appalachian residents (p=0.06). There were
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also no statistical differences in receipt of chemotherapy or hormone therapy between
Appalachian and non-Appalachians.
Conclusion: Our results indicate for the first time no disparity related to breast cancer
diagnosis-treatment intervals in Appalachian Kentucky as compared with the rest of the
state.
Key words: Appalachia, low socio-economic status, cancer, treatment
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Introduction
The breast cancer mortality rate in the United State as a whole has decreased
significantly in recent years, but this rate declined more slowly in Appalachian regions.1
In Kentucky, the age-adjusted death rate due to female breast cancer of Appalachians was
virtually the same as that of non-Appalachian residents during the period from 1995
through 2007.2 Unfortunately, this rate has become higher in Appalachian Kentucky
relative to the other regions within the state in the five recent years, and significantly
higher in 2012 at respective rates of 26.4 per 100,000 (22.8 – 30.3) versus 20.4 per
100,000 (18.4 – 22.6).2 Nevertheless, little research has explored what causes this
disproportionately decreasing trend as well as the disparity related to the breast cancer
mortality rate.3 Most breast cancer death is assumed to be the result of delays in cancer
detection and treatment.4-7 Several studies indicated an association of lower socioeconomic status and increased delays in breast cancer treatment.8-11 Inherent given
geographic isolation and distinguished mountain culture, Appalachian women may suffer
longer delays in breast cancer treatment. However, this potential disparity has not yet
been studied thoroughly because cancer survivorship data for the Appalachian region
from the Surveillance, Epidemiology, and End Results (SEER) program did not become
available until recent years, and information related to individual socio-economic status
has not been collected from the cancer registries.12
To examine the disparity in treatment delays in Appalachian women, we created
the Directed Acyclic Graphs (DAG) to hypothesize a mechanism by which Appalachian
women may be associated with increased delays in beginning treatment for breast cancer
(Figure 1). Appalachian residents are characterized by lower socio-economic status,
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lower income, lower educational attainments, and higher unemployment rates than
residents of other regions within the state.13,14 Such vulnerable status is likely to result in
lower health insurance coverage, later cancer stage at diagnosis, and more comorbid
conditions due to unfavorable health behaviors in Appalachian regions.15 These
consequences may either/both directly cause delays in cancer treatment or/and indirectly
affect the delays through cancer treatment options, which are determined by stage at
diagnosis and comorbid conditions.
In this report, we investigated the association between Appalachian region and
delays in receipt of breast cancer treatment among women included in the Kentucky
Cancer Registry and agreeing to phone surveys within 12 months of their cancer
diagnosis. We hypothesized that Appalachian women with breast cancer would
experience longer delays in treatment initiation as compared with non-Appalachian
women, after adjusting for differences in socio-demographic characteristics and cancer
stage and treatment between the two study groups. Specifically, our research questions
are whether and how Appalachian women with breast cancer are associated with
increased delays in receipt of cancer treatment relative to non-Appalachian women.
Methods
Study Participants
Women aged 18 to 79 who were diagnosed as an incident and primary case of
cancer (excluding squamous cell skin cancer) from December 2009 to August 2014 were
reported to the Kentucky Cancer Registry (KCR). After verifying pathology reports and
checking with the patients’ physician if the patients were approachable, eligible women

4

were sent a letter to participate in the study, enclosed with card stamped and addressed to
KCR staff. KCR staff followed up with women who did not return the card to ask if they
would be willing to talk with University of Kentucky researchers about study
participation. A total of 4628 women with breast cancer were identified by KCR staff as
eligible based on age, incident and primary breast cancer diagnosis confirmed by biopsy,
and diagnosed with in the past 12 months. Of those 4628 women, 2214 agreed to allow
researchers contact (47.8%) and 1245 completed a phone interview (26.9% of all eligible
and 56.2% of those consenting to researcher contact). The phone interview included
questions regarding socio-demographic characteristics, lifestyle factors, and self-reported
comorbidity.
Measures
The cancer treatment outcomes investigated included whether the case received
treatment, if so the cancer treatment type, and the date of first treatment by type. These
data were available from the Kentucky Cancer Registry and abstracted by KCR staff
from case medical records. These data were used to create indicator variables describing
receipt of any treatment, and specific types of treatment included as dichotomous
variables for each treatment option: surgery, chemotherapy, radiation, and hormone
therapy. Additionally, the date of first treatment by type was obtained and used to
determine time to first treatment by type. The following time to treatment variables were
created in which the date of diagnosis was used as the benchmark for time to first
treatment (where time to first is calculated as date of first treatment – date of diagnosis):
first treatment independent of treatment type, time to first surgery, first chemotherapy,
first radiation and first hormone therapy. Time to treatment by type was also calculated
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and included those receiving a specific treatment yet this treatment type was not
necessarily their first. Since the physicians’ recommendation for treatment types is based
on tumor characteristics and patient’s health condition, such as chemotherapy is usually
not part of first course treatment for earlier stages of cancer,16 the cases who were
recommended the treatment but had not received treatment (by type) by KCR medical
abstraction (between 9 – 12 months following a diagnosis) were considered as censored
for survival analyses. Lastly, because we could not determine a physicians’
recommendation for treatment relative to treatment received we explored days to first
treatment (and by treatment type) among those who received the specific type of
treatment. The underlying assumption is that those who received treatment needed that
treatment.
Living in Appalachian Kentucky was the primary exposure of interest. Data to
characterize this status was available from KCR was identified based on Kentucky county
of residence. Breast cancer cases were grouped as Appalachian and non-Appalachian
regions for this cohort analysis.
As described in Figure 1, covariates of potential interest which may impact delays
in cancer treatment included women’s self-report were their (1) family’s monthly income
including assistance from their families (grouped into six categories: less than $1,000;
$1,000 to $1,999; $2,000 to 2,999; $3,000 - $3,999; $4,000 - $4,999; and more than
$5,000), (2) highest educational attainment (groups into five categories: less than high
school, some high school or General Educational Development (GED), college or
vocational certificates, bachelor degree, and post graduate degree), (3) current and
previous smoking status (categorized as never, former and current smokers), (4) current
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marital status (dichotomized as married versus unmarried), and (5) health insurance
coverage (grouped as uninsured including self-pay or no insurance, Medicare, Medicaid
or government plans, and private insurance). Finally, to measure (6) comorbid conditions,
women were asked whether a doctor had ever told them they had any of the following
conditions: a) asthma, chronic bronchitis, emphysema, or chronic obstructive pulmonary
disease, b) high blood pressure or hypertension or high cholesterol, c) heart disease or a
heart attack, d) hepatitis or cirrhosis, e) diabetes, metabolic syndrome or were insulin
resistant, f) irritable bowel syndrome or diverticulitis or diverticulosis, g) fibromyalgia or
chronic fatigue syndrome, and h) stroke or a transient ischemic attack (TIA). Response
options for each condition were yes or no. Physical conditions were summed to create an
ordinal variable indicating the number of conditions the woman has had (frequencies
ranged from 0 to 8 conditions at cancer diagnosis). Two additional predictors of cancer
survival and treatment available from KCR were (7) age at diagnosis (in years), and (8)
stage at cancer diagnosis (defined as carcinoma in situ (=0), localized (=1), regional with
invasion in the immediate area of the tumor site (=2), regional with cancer invasion
beyond the immediate region of the tumor (=3); and distant; cancer invasion to another
site (=4)).
Statistical Analysis
As described in Figure 1, socio-demographic factors may be correlated with
Appalachian region. To determine these associations the Chi-square test for the
proportions of categorical variables or a two-sample t- test for the means of continuous
variables were calculated by Appalachian versus non-Appalachian region (Table 1).
Besides, assessments of collinearity between the covariates indicated that there was no
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significant effect of multicollinearity as the Spearman correlation coefficients of the
factors were less than 0.70, and the variance inflation factors were all less than 10,
similarly (Appendix).
The primary research question evaluated was the association between
Appalachian region and receipt of cancer treatment measures as a dichotomous variable,
as continuous measures of time to treatment among those treated, and as time to
treatment using survival analyses modeling. Three statistical methods were used to
examine the effect of Appalachian residence on cancer treatment among women recently
diagnosed with breast cancer. When cancer treatment was measured simply as receipt of
any treatment and by specific treatment type, unadjusted and adjusted logistic regression
models were used to estimate the odds of treatment among Appalachian and nonAppalachian residence (see Table 2 for results). When days to cancer treatment among
those receiving treatment was used to characterize cancer treatment received, unadjusted
and adjusted linear regression models were used to estimate days to treatment among
those in Appalachian versus non-Appalachian regions (see Table 3 for results). And
finally, when both the proportion treated and time to first treatment were used together to
estimate treatment rate ratios, Cox Proportional Hazards Regression was employed for
estimating rates of treatment initiation following a cancer diagnosis (see Table 4 for
results). These analyses were repeated by type of cancer treatment and within stage of
cancer diagnosis (dichotomized as earlier (stage 0-2) and later (stage 3-4) stage (see
Table 5 for results). Kaplan Meier Curves were produced and presented in figure 2 by
Appalachian versus non-Appalachian region and time to treatment by type. Finally,
diagnostic tests for the final Cox model were provided in the Appendix. Cumulative sums
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of martingale residual plots indicated none of the covariates violated the proportional
hazard assumption and functional form. In terms of influential observations that were
tested by changes of beta coefficient of Appalachian variable in the model and by
changes in over model likelihood, we checked information of the observations, and
contrasted the uncorrected models and the models corrected for influential observations.
As the information was reasonable, and the differences in uncorrected and corrected
models were minor, we reported the uncorrected models for simplicity.
For each model, the following three sets of statistical adjustments to address
covariates were employed (1) the crude estimates to examine the total effect of
Appalachian residence on treatment outcomes, (2) adjustment for age at diagnosis, cancer
stage, and other treatment types which are essential clinical factors for a consideration of
treatment plans,16,17 and (3) the final and more conservative additional adjustment of
family income and health insurance. Statistical Analysis Software, SAS version 9.3 (SAS
Institute; Cary North Carolina) was used for all modeling and statistical analyses.
Results
Among the 1,245 women participating in this study, 334 women lived in the
Appalachian region (26.83%). Relative to women living in non-Appalachian Kentucky,
those living in Appalachia (see Table 1) were more likely to be White (p=.0003), to have
lower income (p<.0001), to receive less education (p<.0001), to be current smokers
(p=.01), to have other than private health insurance (p<.0001), to have more comorbid
conditions (p=.001) and to be diagnosed at a later stage with breast cancer (p=.007). No
regional differences were noted in age at diagnosis and current marital status.
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As represented in Table 2, 1,240 out of 1,245 women with breast cancer received
treatment (99.6%). Similarly the majority (98.4%; 1,225/1,245) received surgery and for
92.5% surgery was the first cancer treatment. No differences by Appalachian region were
noted in receipt of any treatment or receipt of surgery specifically in unadjusted or
adjustment logistic regression models. The proportions of women receiving
chemotherapy, radiation or hormone therapy as the first course of treatment were
significantly lower in Appalachian women in comparison to these of non-Appalachian
women regardless of control for age, stage and treatment types in logistic regression
models. When we adjusted for these factors along with individual income and health
insurance only odds ratio for receipt of radiation remained statistical significant but not
for receipt of chemotherapy or hormone therapy.
The results of the analyses addressing days to treatment among those receiving
treatment by Appalachian residence are provided in Table 3. Number of days between
diagnosis date and first treatment date as our outcome of interest were statistically
different between the Appalachian and non-Appalachian groups (the means were 19.87
versus 23.10, with a p-value for a t-test of 0.02 when adjusting for age, and stage yet
when additionally (and more conservatively) adjusting for income and health insurance,
regional differences were no longer significant. Briefly, women living in Appalachian
Kentucky had fewer days to first treatment (p<.05) than did women living in NonAppalachian Kentucky. This pattern was observed for days to first treatment, surgery,
radiation, and hormone therapy when considered adjusted models. No regional
differences in time to treatment were observed for chemotherapy between the two study
groups.
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Figure 2 illustrates the Kaplan-Meier curves for time to treatment by Appalachian
region. Since p values of the Log Rank test for the time to any first treatment and time to
first surgery were less than a five percent significance level, we have strong evidence to
conclude that the curves are different when comparing Appalachian breast cancer women
versus non-Appalachian breast cancer women, not taking into account any other covariate
information. Yet we failed to reject the null hypothesis that the curves for the time to first
chemotherapy or the time to first radiation or the time to hormone therapy were the same
for the two groups at all points in time.
The results of the Cox proportional hazards model with and without covariate
adjustments are provided in Table 4; time to median treatment probability by
Appalachian region were provided as well as the hazard ratios for cancer treatment by
type. The unadjusted hazard ratio for any treatment received of 1.17 [95% CI: (1.04 –
1.33)] indicates that women in Appalachian Kentucky were 17% more likely to receive
any cancer treatment earlier than women living in Non-Appalachian regions. While this
association remained significant when adjusting for age and stage at diagnosis (HR=
1.14; 95% CI=1.01 – 1.30), the more conservative adjustment for age, stage at diagnosis,
income and health insurance resulted in a HR of 1.11 [95% CI: (0.97 – 1.28)] was no
longer significant. This finding does suggest that the effect of Appalachian residence on
time to any first cancer treatment may be mediated by income or insurance and not
simply residence. Appalachian women appeared be more likely to receive surgery and
radiation earlier than women living in Non-Appalachian regions (note differences in
findings by adjustments in models).
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When these analyses were repeated by stage at cancer diagnosis (Table 5) similar
findings were observed for Appalachian residence being more likely to receive any and
specifically surgery sooner than Non-Appalachian residents among those diagnosed at an
earlier stage (0-2). No difference in treatment by Appalachian were noted among women
diagnosed at later stage.
Discussion
In this cohort analysis, Appalachian women diagnosed with breast cancer tended
to receive any first cancer treatment or first surgery slightly sooner than those in nonAppalachian regions. By adjusting for individual income, health insurance, other types of
treatment, age and cancer stage at diagnosis the differences in rates of treatment initiation
were not statistically significant. The findings did not concur with our hypothesis that
women living in underserved Appalachian region might suffer delays in breast cancer
treatment. Since this is the first study to explore time to first cancer treatment by type
among women diagnosed with breast cancer in Appalachia compared to those living in
the rest of Kentucky, we are thus not able to compare our results with others. The results
might be partially explained by the higher proportion of the Appalachian women who
were diagnosed and treated on the same day compared to that of non-Appalachian
women (20.42% versus 16.65%, a p value for the Chi-square test of 0.12). Moreover,
while the proportion of patients at stage 4 was higher in the Appalachian group compared
to the non-Appalachian group, the patients at stage 4 were likely to initiate treatment
sooner. By contrast, the proportion of patients at stage 0 was lower in Appalachian
Kentucky, whereas the women at stage 0 were likely to start treatment later. Women with
monthly income from $4,000 to $4,999, which was observed less often in Appalachian
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group tended to have a longer delay in cancer treatment. Yet the patients with a medium
level of income, who may have underlying factors such as current employment, would
take a longer time to arrange for a treatment.
Our results indicate a four-day difference in the mean or median number of days
from diagnosis to any first treatment and a five-day difference in the mean or median
number of days from diagnosis to first surgery between the two study groups. A recent
study reported a treatment delay of more than 60 days to be associated with an increased
risk of breast cancer-related death among patients at late stages.10 We might also over
adjust when controlling individual’s insurance and income along with essential clinical
factors that affect the treatment options. However, the findings might be good news if we
can say that clinicians recognize the burden of distance of travel burden and get those
from greater distance into treatment sooner.
In the Cox regression models, due to differences in treatment plans recommended
for the patients we considered censors as cases who were recommended a treatment type
but had not received that treatment. It is reasonable to exclude those who were not
recommended for a treatment when rates of receiving specific types of treatment were
estimated. For instance, 98% (54/55) of the cases at stage 0, and 60% of the cases at stage
1 were not recommended for chemotherapy, and were thus excluded in the analysis of
time to first chemotherapy, whereas only 15% of the cases at stage 3 were not
recommended for chemotherapy. However, analyses also suggested that Appalachian
women were less likely to be recommended for a chemotherapy or radiation or hormone
therapy as compared with non-Appalachian women. Without controlling for potential
confounders such as cancer stage, radiation was recommended for 63% of non-
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Appalachian women while it was recommended for only 54% of Appalachian women
(p=.007). Hormone therapy was recommended for 73% of non-Appalachian women
versus for 69% of Appalachians (p=.17). Chemotherapy was recommended for 55% of
non-Appalachian women versus for 52% of Appalachians (p=.38). The results imply that
our exclusion of patients who were not recommended for a specific treatment type might
overshadow treatment-related disparities in the Appalachian regions. They also raise
another important question for further study, whether non-clinical patient factors,
including living in Appalachian regions influence doctors’ recommendation for treatment
plans in our study. Some previous studies suggested that patient’s circumstances related
to health insurance, travel difficulties or income play a role in medical oncologist
decision-making for cancer treatment recommendations.18-22
Our study has several strengths. This is the first longitudinal study design to
compare time from diagnosis to first treatment among Appalachian women diagnosed
with breast cancer versus those in the rest of the state. This study also considers the
effects of numerous potential predictors on diagnosis-treatment time intervals by various
statistical models. In addition, missing data and recall bias are very limited in our study.
There is also little to no chance of differential misclassification of outcome and exposure
as the study subjects were not reporting either Appalachian status or date of treatment by
type. Thus only non-differential misclassification that introduces a bias toward the null
might occur.
However, our study contains some limitations. First and foremost, time to cancer
treatment that was determined from date of confirmed diagnosis to date of treatment only
reflects treatment delays among the women who present at health facilities for a cancer
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diagnosis, but does not measure the delays among those who are unable to access health
services to be diagnosed. This may lead to underestimation of actual delays in cancer
treatment. Comprehensive assessments of delays, including primary delays (duration
between onsets of the symptoms and contacting health professionals), secondary delays
(time interval of presenting at a health facility and getting a confirmed diagnosis), and
these tertiary delays can be used for strengthening the results. Additional measures
known to influence treatment delays, such as physician-related delays before and after
diagnosis may also have been beneficial to gather and include in our regression model.
Another limitation to our study is non-response bias that may be present, and
questionable generalizability of the findings due to a low response rate (22.3%).
However, there was no statistical difference in response rates between Appalachian
women (24.6%) and non-Appalachian women (23.0%), which might mitigate the bias.
Furthermore, extension of the study locations to other cancer registries in Appalachian
areas to increase generalizability and further assess covariate effects such as women’s
educational attainment, employment, or income, may be helpful in assessing the impact
of Appalachian residence on time to first cancer treatment.
In conclusion, our study contributes to the literature with regards to duration
between diagnosis and treatment dates among women with breast cancer in Appalachian
Kentucky in comparison to the rest within the state. While the study results did not reveal
the disparity related to delays in initiating breast cancer treatment in Appalachian women
as compared to non-Appalachian women in Kentucky, efforts to improve the breast
cancer screening programs in order to reduce late breast cancer diagnosis for Appalachian
women should continue to be.
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Table 1: Demographic Profile of Women with Breast Cancer by Appalachian Residence, 2009 - 2014
All women

Appalachian

Non-Appalachian

P value (χ2 or t test)

Age at Diagnosis

N=1,245

N=334

N=911

p= 0.12 (t df=1243=-1.55)

Mean (SD)

56.61 (9.90)

57.33 (9.91)

56.35 (9.89)

N=1,240

N=333

N=907

1,174 (94.68%)

328 (98.50%)

846 (93.27%)

66 (5.32%)

5 (1.50%)

61 (6.73%)

N=1,018

N=286

N=732

<$1,000

102 (10.02%)

39 (13.64%)

63 (8.61%)

$1,000 - $1,999

201 (19.74%)

83 (29.02%)

118 (16.12%)

$2,000 – 2,999

151(14.83%)

48 (16.78%)

103 (14.07%)

$3,000 - $3,999

140 (13.75%)

30 (10.49%)

110 (15.03%)

$4,000 - $4,999

112 (11.0%)

31 (10.84%)

81 (11.07%)

≥$5,000

312 (30.65%)

55 (19.23%)

257 (35.11%)

N=1,244

N=334

N=910

Less than High School

101 (8.12%)

52 (15.57%)

49 (5.38%)

High School/ GED

403 (32.40%)

123 (36.83%)

280 (30.77%)

College/Technical

224 (18.01%)

51 (15.27%)

173 (19.01%)

Bachelor Degree

164 (13.18%)

49 (14.67%)

115 (12.64%)

Post Graduate Degree

352 (28.30%)

59 (17.66%)

293 (32.20%)

Variables

Race
White
Non-White
Woman’s Monthly Income

Woman’s Educational Attainment

p<0.0003 (χ2df=1=13.19)

p<0.0001 (χ2df=5=43.55)

p<0.0001 (χ2df=4=54.88)
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Variables

All women

Appalachian

Non-Appalachian

N=1,244

N=334

N=910

Married

848 (68.17%)

232 (69.46%)

616 (67.69%)

Unmarried

396 (31.83%)

102 (30.54%)

294 (32.31%)

N=1,245

N=334

N=911

Never smoker

707 (56.79%)

185 (55.39%)

522 (57.30%)

Current smoker

153 (12.29%)

56 (16.77%)

97 (10.65%)

Former smoker

385 (30.92%)

93 (27.84%)

292 (32.05%)

N=1,245

N=334

N=911

Private insurance

795 (63.86%)

174 (52.10%)

621 (68.17%)

Medicaid/Military

97 (7.79%)

35 (10.48%)

62 (6.81%)

321 (25.78%)

108 (32.34%)

213 (23.38%)

32 (2.57%)

17 (5.09%)

15 (1.65%)

N=1,241

N=333

N=908

1.62 (1.24)

1.82 (1.37)

1.55 (1.19)

N=1,245

N=334

N=911

Stage 0

55 (4.42%)

7 (2.10%)

48 (5.27%)

Stage 1

826 (66.35%)

227 (67.96%)

599 (65.75%)

Stage 2

18 (1.45%)

4 (1.20%)

14 (1.54%)

Stage 3

313 (25.14%)

80 (23.95%)

233 (25.58%)

Stage 4

33 (2.65%)

16 (4.79%)

17 (1.87%)

Current Marital Status

Woman’s Smoking Status

Health Insurance or Plans

Medicare
Not Insured
Number of Comorbid Conditions
Mean (SD)
Cancer Stage at Diagnosis

P value (χ2 or t test)
p=0.55 (χ2df=1=0.35)

p=0.01 (χ2df=2=9.00)

p<0.0001 (χ2df=3= 32.99)

p=0.001 (tdf=527=-3.24)
p=0.007 (χ2df=4=14.09)
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Table 2: Appalachian Residence and Type of Cancer Treatment Received among Women Diagnosed with Breast Cancer, 2009
- 2014
Variables

All women
n (%)

Appalachian
n (%)

Non-Appalachian
n (%)

Yes

1,240 (99.60%)

333 (99.70%)

907 (99.56%)

No

5 (0.40%)

1 (0.30%)

4 (0.44%)

Yes

1,225 (98.39%)

326 (97.60%)

899 (98.68%)

No

20 (1.61%)

8 (2.40%)

12 (1.32%)

Yes

1,151 (92.45%)

310 (92.81%)

841 (92.32%)

No

94 (7.55%)

24 (7.19%)

70 (7.68%)

Yes

599 (48.11%)

145 (43.41%)

454 (49.84%)

No

646 (51.89%)

189 (56.59%)

457 (50.16%)

73 (5.86%)

21 (6.29%)

52 (5.71%)

Appalachian versus Non-Appalachian
Unadjusted
Adjusted OR*
Adjusted
OR (95% CI)
(95% CI)
OR** (95%CI)

Received treatment
1.47***
(0.16 – 13.19)

1.44
(0.16 – 12.97)

1.44
(0.15 – 13.59)

0.54
(0.22 – 1.34)

1.07
(0.38 – 2.99)

1.004
(0.32 – 3.18)

1.08
(0.66 - 1.74)

1.31
(0.77 – 2.23)

1.38
(0.76 – 2.52)

0.77
(0.60 – 0.99)

0.68
(0.51 – 0.92)

0.66
(0.48 – 0.93)

1.11

0.95

0.84

Received surgery

First treatment was
surgery

Received
chemotherapy

First treatment was
chemotherapy
Yes
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Variables

All women
n (%)

Appalachian
n (%)

Non-Appalachian
n (%)

1,172 (94.14%)

313 (93.71%)

859 (94.29%)

Yes

691 (55.50%)

156 (46.71%)

535 (58.73%)

No

554 (44.50%)

178 (53.29%)

376 (41.27%)

Yes

2 (0.08%)

0

2 (0.22%)

No

1,234 (99.12%)

334 (100%)

909 (99.78%)

Yes

805 (64.66%)

196 (58.68%)

609 (66.85%)

No

440 (35.34%)

138 (41.32%)

302 (33.15%)

Yes

23 (1.85%)

6 (1.80%)

17 (1.87%)

No

1222 (98.15%)

328 (98.20%)

894 (98.13%)

No

Appalachian versus Non-Appalachian
Unadjusted
Adjusted OR*
Adjusted
OR (95% CI)
(95% CI)
OR** (95%CI)
(0.66 – 1.87)
(0.53 – 1.72)
(0.42 – 1.70)

Received radiation
0.62
(0.48 – 0.79)

0.65
(0.50 – 0.85)

0.68
(0.50 – 0.91)

***

***

***

0.70
(0.54 – 0.91)

0.69
(0.52 – 0.92)

0.77
(0.57 – 1.04)

0.96
(0.38 – 2.46)

0.65
(0.23 – 1.88)

0.78
(0.25 – 2.43)

First treatment was
radiation

Received hormone

First treatment was
hormone

*Odds ratios (OR) for receipt of cancer treatment, controlling for age at diagnosis, cancer stage, and other treatment received (except
for specific treatment as first). 95% confidence intervals (CI) are given in parentheses.
** ORs for receipt of cancer treatment, controlling for age at diagnosis, cancer stage, other treatment received (except for specific
treatment as first), income and health insurance. 95% CIs are given in parentheses.
***Unstable ORs due to the small number of women who received or did not received a treatment.
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Table 3: Appalachian Residence and Time to First Treatment by Type among Women Receiving the Specific Treatment, 2009
– 2014
Variables

Unadjusted mean days to cancer treatment (SE)

β estimate (95% CI) for Appalachian versus NonAppalachian

All women

Appalachian

Non-Appalachian

Unadjusted

Adjusted*

Adjusted**

Days to first
treatment

22.23 (0.53)

19.87 (1.02)

23.10 (0.62)

-3.23
(-5.56; -0.89)
p= 0.007

-2.79
(-5.13; -0.45)
p= 0.02

-2.18
(-4.84; 0.49)
p= 0.11

Days to first
surgery

28.94 (1.05)

24.18 (1.68)

30.67 (1.29)

-6.5
(-11.14; -1.85)
p= 0.01

-5.89
(-10.5;-1.29)
p=0.01

-5.39
(-10.49; -0.29)
p =0.04

Days to surgery
where surgery is
first treatment

21.88 (0.55)

19.38 (1.06)

22.80 (0.65)

-3.42
(-5.86; -0.98)
p= 0.006

-3.13
(-5.60;-0.66)
p= 0.01

-2.45
(-5.22; 0.33)
p= 0.08

Days to first
chemotherapy

62.91 (1.31)

63.69 (2.96)

62.66 (1.45)

1.03
(-5.00; 7.06)
p=0.74

2.83
(-2.96; 8.62)
p=0.34

3.06
(-3.46; 9.58)
p=0.36

Days to
chemotherapy
where
chemotherapy is
first treatment

27.00 (1.89)

26.57 (3.22)

27.17 (2.33)

-0.60
(-8.98; 7.77)
p=0.89

-3.70
(-12.55; 5.14)
p=0.41

-2.02
(-13.61; 9.57)
p=0.73
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Variables

Unadjusted mean days to cancer treatment (SE)

β estimate (95% CI) for Appalachian versus NonAppalachian

All women

Appalachian

Non-Appalachian

Unadjusted

Adjusted*

Adjusted**

Days to first
radiation

137.92 (3.15)

129.30 (7.31)

140.40 (3.46)

-11.14
(-25.9; 3.62)
p=0.14

-8.37
(-17.82; 1.08)
p=0.08

-14.46
(-25.12; -3.8)
p =0.01

Days to hormone
therapy

134.84 (3.32)

124.10 (6.50)

138.30 (3.84)

-14.23
(-29.37; 0.92)
p=0.07

-7.88
(-19.84; 4.09)
p=0.20

-13.06
(-26.02; -0.1)
p=0.048

Days to hormone
therapy where
hormone therapy
is first treatment

19.70 (3.53)

12.33 (5.44)

22.29 (4.28)

-9.96
(-26.48; 6.56)
p=0.22

8.21
(-7.98; 24.41)
p=0.30

11.69
(-23.34; 46.71)
p=0.45

*SE: Standard error
* Non-intercept parameter estimates (β) for receipt of cancer treatment, controlling for age at diagnosis, cancer stage, and other
treatment received (except for specific treatment as first). 95% confidence intervals (CI) are given in parentheses.
** β estimates for receipt of cancer treatment, controlling for age at diagnosis, cancer stage, other treatment received (except for
specific treatment as first), income and health insurance. 95% CIs are given in parentheses
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Table 4: Survival Analyses: Appalachian Residence and First Cancer Treatment among Women with Breast Cancer, 2009 2014
Outcomes

Median Treatment Time* (95% CI)

HR (95% CI) for Appalachian versus Non-Appalachian

Appalachian

Non-Appalachian

Unadjusted

Adjusted HR**

Adjusted HR***

Time to First
Treatment

16 (14 – 18)
N=334

21 (20 – 22)
N=911

1.17 (1.04 – 1.33)
p=0.01

1.14 (1.01 – 1.30)
p=0.04

1.11 (0.97 – 1.28)
p=0.14

Time to first
surgery

17 (15 – 20)
N=334

22 (21 – 23)
N=911

1.14 (1.002 – 1.29)
p=0.046

1.18 (1.03 – 1.34)
p=0.01

1.14 (0.99 – 1.32)
p=0.08

Time to first
chemotherapy

60 (52 – 65)
N=155

62 (57 – 65)
N=480

0.96 (0.79 – 1.15)
p=0.64

0.88 (0.72 – 1.06)
p=0.17

0.84 (0.68 – 1.04)
p=0.12

Time to first
radiation

110 (86 – 143)
N=161

145 (118 – 160)
N=549

1.11 (0.93 – 1.33)
p=0.26

1.16 (0.97 – 1.39)
p=0.11

1.33 (1.08 – 1.62)
p=0.006

Time to first
hormone

103.50 (82 – 136)
N=206

126 (114 – 137)
N=624

1.02 (0.87 – 1.20)
p=0.83

0.97 (0.83 – 1.15)
p=0.75

1.07 (0.89 – 1.28)
p=0.50

* Time point at which 50% of patients have received first cancer treatment by Kaplan Meijer method
** Cox proportional hazards regression models: Hazard ratios (HR) for receipt of cancer treatment, controlling for age at diagnosis,
cancer stage, and other treatment received (except for specific treatment as first). 95% confidence intervals (CI) are given in
parentheses.
*** Cox proportional hazards regression models: HRs estimates for receipt of cancer treatment, controlling for age at diagnosis,
cancer stage, other treatment received (except for specific treatment as first), income and health insurance. 95% CIs are given in
parentheses.
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Table 5: Survival Analyses: Appalachian Residence and First Cancer Treatment among Women Recently Diagnosed with
Breast Cancer, Stratified by Cancer Stage, 2009 - 2014
Outcomes

Median Treatment Time* (95% CI)
Appalachian

Non-Appalachian

HR (95% CI) for Appalachian versus Non-Appalachian
Unadjusted

Adjusted **

Adjusted ***

Among women diagnosed with earlier stage breast cancer - Stage 0 – 2 (N=899)
Time to first
treatment

17 (15 – 19)

21 (20 – 23)

1.25 (1.08 – 1.45)

1.23 (1.06 – 1.43)

1.18 (0.999 – 1.39)

N=238

N=661

p=0.003

p=0.006

p=0.051

Time to first
surgery

17 (15 – 20)

22 (20 – 23)

1.21 (1.04 – 1.40)

1.22 (1.05 – 1.42)

1.18 (0.997 – 1.40)

N=238

N=661

p=0.01

p=0.01

p=0.055

Time to first
chemotherapy

68 (60 – 78)

66.5 (62 – 70)

0.93 (0.72 – 1.20)

0.87 (0.66 – 1.13)

0.83 (0.62 – 1.12)

N=81

N=266

p=0.57

p=0.29

p=0.23

Time to first
radiation

85 (70 – 99)

83 (75 – 95)

1.10 (0.88 – 1.36)

1.12 (0.90 – 1.39)

1.21 (0.94 – 1.55)

N=107

N=381

p=0.41

p=0.33

p=0.14

Time to first
hormone

85 (70 – 108)

98 (88 – 110)

0.99 (0.82 – 1.20)

1.03 (0.85 – 1.24)

1.11 (0.90 – 1.38)

N=148

N=448

p=0.89

p=0.80

p=0.33

Among women diagnosed with later stage breast cancer - Stage 3 – 4 (N=346)
Time to first
treatment

15 (12 – 21)

19 (16 – 22)

N=96

N=250

0.998 (0.79 – 1.27) 0.997 (0.79 – 1.26)
p=0.99

p=0.98

1.03 (0.78 – 1.36)
p=0.85
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Outcomes

Median Treatment Time* (95% CI)

HR (95% CI) for Appalachian versus Non-Appalachian

Appalachian

Non-Appalachian

Unadjusted

Adjusted **

Adjusted ***

16.5 (14 – 24)

23 (19 – 26)

1.08 (0.85 – 1.37)

1.10 (0.86 – 1.40)

1.08 (0.81 – 1.44)

N=96

N=250

p=0.55

p=0.46

p=0.60

52 (46 – 61)

55.5 (51 – 59)

0.96 (0.73 – 1.26)

0.93 (0.71 – 1.23)

0.92 (0.67 – 1.25)

N=74

N=214

p=0.78

p=0.61

p=0.58

Time to first
radiation

188 (146 – 207)

212 (203 – 220)

1.15 (0.84 – 1.57)

1.05 (0.76 – 1.44)

1.42 (0.99 – 2.05)

N=54

N=168

p=0.39

p=0.78

p=0.06

Time to first
hormone

183 (128 – 209)

183.5 (178 – 202)

1.08 (0.80 – 1.46)

0.89 (0.65 – 1.22)

0.98 (0.67 – 1.43)

N=58

N=176

p=0.62

p=0.47

p=0.92

Time to first
surgery
Time to first
chemotherapy

* Time point at which 50% of patients have received first cancer treatment by Kaplan Meijer method
** Cox proportional hazards regression models: Hazard ratios (HR) for receipt of cancer treatment, controlling for age at diagnosis,
and other treatment received (except for specific treatment as first). 95% confidence intervals (CI) are given in parentheses.
*** Cox proportional hazards regression models: HRs estimates for receipt of cancer treatment, controlling for age at diagnosis, other
treatment received (except for specific treatment as first), income and health insurance. 95% CIs are given in parentheses
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Figure 1: Directed Acyclic Graph (DAG) depicting a hypothesized mechanism for association of Appalachian women and
delays in receipt of cancer treatment - Created with the online Dagitty at: http://www.dagitty.net/dags.html#

Minimal sufficient adjustment sets containing age at diagnosis for estimating the direct effect of Appalachian women on
delays in receipt of cancer treatment: stage at diagnosis, socio-economic status and health insurance or plans
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Figure 2: Kaplan Meijer Curves
Figure 2a. Time to First Breast Cancer Treatment
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Figure 2b. Time to First Surgery
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Figure 2c. Time to First Chemotherapy

Test
Log-Rank
Wilcoxon
-2Log(LR)

Test of Equality over Strata
Chi-Square
DF
0.2283
0.0068
0.0044

Pr >
Chi-Square
1
1
1

0.6328
0.9343
0.9473

32

Figure 2d. Time to First Radiation Therapy
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Figure 2e. Time to First Hormone Therapy
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Appendix
Table 6: Full Cox proportional hazards regression models for time to any type of
treatment
Predictor

Unadjusted HR
(95% CI)

Adjusted HR*
(95% CI)

Adjusted HR**
(95% CI)

Appalachian Region:
Appalachian
Non-Appalachian

p=0.01
1.17 (1.04 – 1.33)
Reference

p=0.04
p=0.14
1.14 (1.01 – 1.30) 1.11 (0.97 – 1.28)
Reference
Reference

Age at Diagnosis:

p=0.01
1.01 (1.002–1.01)

p=0.02
1.01 (1.001–1.01)

p=0.20
1.01 (0.99 – 1.01)

Stage at Diagnosis:
Stage 0
Stage 1
Stage 2 and Stage 3
Stage 4

p=0.07
0.57 (0.37 – 0.88)
0.76 (0.54 – 1.08)
0.74 (0.52 – 1.06)
Reference

p=0.14
0.61 (0.39 – 0.94)
0.79 (0.55 – 1.12)
0.77 (0.53 – 1.10)
Reference

p=0.26
0.61 (0.37 – 1.01)
0.80 (0.54 – 1.18)
0.79 (0.52 – 1.17)
Reference

Monthly Income:
<$1,000
$1,000 - $1,999
$2,000 – 2,999
$3,000 - $3,999
$4,000 - $4,999
≥$5,000

p=0.04
Reference
1.46 (1.15 – 1.86)
1.33 (1.03 – 1.71)
1.35 (1.05 – 1.75)
1.14 (0.87 – 1.50)
1.24 (0.99 – 1.55)

p=0.09
Reference
1.40 (1.09 – 1.79)
1.32 (1.01 – 1.73)
1.37 (1.04 – 1.80)
1.13 (0.85 – 1.51)
1.28 (1.00 – 1.64)

Health Insurance:
Uninsured
Medicaid
Medicare
Private insurance

p=0.11
1.15 (0.81 – 1.64)
0.87 (0.70 – 1.07)
1.12 (0.98 – 1.27)
Reference

p=0.75
0.94 (0.61 – 1.45)
0.93 (0.73 – 1.20)
1.07 (0.89 – 1.27)
Reference

95% Confidence Interval (95% CI) of the hazards ratios are given in parentheses
*Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at
diagnosis and stage at diagnosis
** Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at
diagnosis, stage at diagnosis, family’s monthly income and health insurance
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Table 7: Full Cox proportional hazards regression model for time to first surgery
Predictor

Unadjusted HR

Adjusted HR*

Adjusted HR**

(95% CI)

(95% CI)

(95% CI)

p=0.046

p=0.01

p=0.08

1.14 (1.002–1.29)

1.18 (1.03 – 1.34)

1.14 (0.99 – 1.32)

Reference

Reference

Reference

p<0.001

p<0.0001

p=0.01

1.02 (1.01–1.02)

1.01 (1.01 – 1.02)

1.01 (1.002–1.02)

p<0.0001

p<0.0001

p<0.0001

Stage 0

2.26 (1.40 – 3.65)

2.38 (1.46 – 3.87)

2.14 (1.25 – 3.65)

Stage 1

2.60 (1.74 – 3.90)

2.58 (1.71 – 3.87)

2.31 (1.50 – 3.55)

Stage 2 and Stage 3

2.01 (1.33 – 3.03)

2.01 (1.33 – 3.04)

1.81 (1.17 – 2.81)

Reference

Reference

Reference

Appalachian Region:
Appalachian
Non-Appalachian
Age at Diagnosis:

Stage at Diagnosis:

Stage 4

p=0.17

p=0.41

Reference

Reference

$1,000 - $1,999

1.34 (1.05 – 1.71)

1.22 (0.95 – 1.56)

$2,000 – 2,999

1.23 (0.95 – 1.59)

1.19 (0.90 – 1.56)

$3,000 - $3,999

1.28 (0.99 – 1.66)

1.19 (0.90 – 1.57)

$4,000 - $4,999

1.09 (0.83 – 1.43)

1.02 (0.76 – 1.36)

≥$5,000

1.25 (0.99 – 1.58)

1.21 (0.94 – 1.55)

Health Insurance:

p=0.0007

p=0.09

Uninsured

1.03 (0.72 – 1.48)

1.23 (0.80 – 1.87)

Medicaid

0.79 (0.63 – 0.98)

0.80 (0.62 – 1.03)

Medicare

1.22 (1.08 – 1.40)

1.10 (0.92 – 1.32)

Reference

Reference

Monthly Income:
<$1,000

Private insurance

p=0.002

p=0.54

p=0.93

Yes

0.84 (0.75 – 0.94)

0.96 (0.84 – 1.09)

0.99 (0.86 – 1.15)

No

Reference

Reference

Reference

Chemotherapy:
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Predictor

Unadjusted HR

Adjusted HR*

Adjusted HR**

(95% CI)

(95% CI)

(95% CI)

Radiation:

p=0.005

p=0.005

p=0.006

Yes

1.18 (1.05 – 1.32)

1.18 (1.05 – 1.33)

1.20 (1.05 – 1.37)

No

Reference

Reference

Reference

p=0.10

p=0.22

p=0.54

Yes

1.11 (0.98 – 1.25)

1.08 (0.95 – 1.22)

1.04 (0.91 – 1.20)

No

Reference

Reference

Reference

Hormone Therapy:

95% Confidence Interval (95% CI) of the hazards ratios are given in parentheses
*Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at
diagnosis, other types of treatment and stage at diagnosis
** Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at
diagnosis, stage at diagnosis, other types of treatment, family’s monthly income and
health insurance
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Table 8: Full Cox proportional hazards regression models for time to first
chemotherapy
Predictor

Appalachian Region:
Appalachian
Non-Appalachian

Unadjusted HR

Adjusted HR*

Adjusted HR**

(95% CI)

(95% CI)

(95% CI)

p=0.64

p=0.17

p=0.12

0.96 (0.79 – 1.15)

0.88 (0.72 – 1.06) 0.84 (0.68 – 1.04)

Reference

Reference

Reference

p<0.0001

p<0.0001

p=0.0008

0.98 (0.97 – 0.99)

0.98 (0.97 – 0.99)

0.98 (0.97–0.99)

p<0.0001

p<0.0001

p<0.0001

Stage 0

1.63 (0.22–12.15)

2.39 (0.32–17.94)

2.61 (0.34–19.94)

Stage 1

0.32 (0.21 – 0.50)

0.37 (0.24 – 0.58)

0.41 (0.25 – 0.67)

Stage 2 and Stage 3

0.47 (0.30 – 0.72)

0.54 (0.35 – 0.86)

0.64 (0.39 – 1.05)

Reference

Reference

Reference

Age at Diagnosis:

Stage at Diagnosis:

Stage 4

p=0.09

p=0.007

Reference

Reference

$1,000 - $1,999

1.65 (1.16 – 2.33)

2.08 (1.44 – 3.01)

$2,000 – 2,999

1.47 (1.01 – 2.15)

1.58 (1.06 – 2.37)

$3,000 - $3,999

1.28 (0.88 – 1.85)

1.44 (0.97 – 2.13)

$4,000 - $4,999

1.30 (0.90 – 1.88)

1.53 (1.03 – 2.27)

≥$5,000

1.49 (1.07 – 2.06)

1.56 (1.09 – 2.25)

Health Insurance:

p=0.0009

p=0.20

Uninsured

1.02 (0.65 – 1.60)

0.80 (0.47 – 1.35)

Medicaid

0.94 (0.71 – 1.24)

0.93 (0.66 – 1.31)

Medicare

0.65 (0.53 – 0.80)

0.75 (0.57 – 0.98)

Private insurance

Reference

Reference

Surgery:

p<0.0001

p<0.0001

p=0.0008

0.20 (0.11 – 0.38)

0.27 (0.14 – 0.52)

0.30 (0.15 – 0.61)

Monthly Income:
<$1,000

Yes
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Predictor

Unadjusted HR

Adjusted HR*

Adjusted HR**

(95% CI)

(95% CI)

(95% CI)

No

Reference

Reference

Reference

Radiation:

p=0.15

p=0.07

p=0.32

Yes

1.13 (0.96 – 1.33)

1.17 (0.99 – 1.38)

1.10 (0.91 – 1.33)

No

Reference

Reference

Reference

p<0.0001

p<0.0001

p<0.0001

Yes

0.69 (0.59 – 0.82)

0.67 (0.56 – 0.79)

0.61 (0.50 – 0.74)

No

Reference

Reference

Reference

Hormone Therapy:

95% Confidence Interval (95% CI) of the hazards ratios are given in parentheses
*Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at
diagnosis, other types of treatment and stage at diagnosis
** Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at
diagnosis, stage at diagnosis, other types of treatment, family’s monthly income and
health insurance
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Table 9: Full Cox proportional hazards regression models for time to first radiation
Predictor

Appalachian Region:
Appalachian
Non-Appalachian

Unadjusted HR

Adjusted HR*

Adjusted HR**

(95% CI)

(95% CI)

(95% CI)

p=0.26

p=0.11

p=0.006

1.11 (0.93 – 1.33)

1.16 (0.97 – 1.39) 1.33 (1.08 – 1.62)

Reference

Reference

Reference

p=0.001

p=0.28

p=0.69

1.01 (1.01 – 1.02)

0.99 (0.99–1.004)

0.99 (0.99–1.01)

p<0.0001

p<0.0001

p<0.0001

Stage 0

1.11 (0.57 – 2.18)

0.65 (0.33 – 1.29)

0.90 (0.44–1.88)

Stage 1

0.98 (0.57 – 1.66)

0.94 (0.55 – 1.61)

1.02 (0.59 – 1.77)

Stage 2 and Stage 3

0.41 (0.24 – 0.71)

0.55 (0.32 – 0.94)

0.60 (0.34 – 1.06)

Reference

Reference

Reference

Age at Diagnosis:

Stage at Diagnosis:

Stage 4

p=0.04

p=0.17

Reference

Reference

$1,000 - $1,999

1.40 (0.99 – 1.98)

1.03 (0.72 – 1.48)

$2,000 – 2,999

1.71 (1.18 – 2.47)

1.10 (0.73 – 1.64)

$3,000 - $3,999

1.39 (0.97 – 2.00)

0.74 (0.50 – 1.11)

$4,000 - $4,999

1.30 (0.89 – 1.90)

0.89 (0.59 – 1.36)

≥$5,000

1.61 (1.17 – 2.22)

1.02 (0.71 – 1.47)

Health Insurance:

p=0.004

p<0.0001

Uninsured

0.97 (0.60 – 1.57)

0.86 (0.48 – 1.53)

Medicaid

0.58 (0.43 – 0.78)

0.43 (0.30 – 0.62)

Medicare

0.91 (0.76 – 1.09)

0.59 (0.46 – 0.76)

Private insurance

Reference

Reference

Monthly Income:
<$1,000

p=0.18

p=0.01

p=0.02

Yes

3.86 (0.54–27.54)

11.7 (1.63–83.91)

10.92 (1.48–80.67)

No

Reference

Reference

Reference

Surgery:
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Predictor

Unadjusted HR

Adjusted HR*

Adjusted HR**

(95% CI)

(95% CI)

(95% CI)

p<0.0001

p<0.0001

p<0.0001

Yes

0.26 (0.22 – 0.31)

0.30 (0.25 – 0.37)

0.25 (0.20 – 0.31)

No

Reference

Reference

Reference

p<0.0001

p<0.0001

p=0.003

Yes

1.55 (1.31 – 1.83)

1.48 (1.24 – 1.77)

1.34 (1.11 – 1.63)

No

Reference

Reference

Reference

Chemotherapy:

Hormone Therapy:

95% Confidence Interval (95% CI) of the hazards ratios are given in parentheses
*Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at
diagnosis, other types of treatment and stage at diagnosis
** Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at
diagnosis, stage at diagnosis, other types of treatment, family’s monthly income and
health insurance
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Table 10: Full Cox proportional hazards regression models for time to first hormone
therapy
Predictor

Appalachian Region:
Appalachian
Non-Appalachian

Unadjusted HR

Adjusted HR*

Adjusted HR**

(95% CI)

(95% CI)

(95% CI)

p=0.83

p=0.75

p=0.50

1.02 (0.87 – 1.20)

0.97 (0.83 – 1.15) 1.07 (0.89 – 1.28)

Reference

Reference

Reference

p<0.0001

p=0.55

p=0.16

1.02 (1.01 – 1.03)

1.002 (0.99–1.01)

1.01 (0.997–1.02)

p<0.0001

p=0.0002

p=0.01

Stage 0

0.65 (0.37 – 1.17)

0.30 (0.17 – 0.55)

0.38 (0.19–0.75)

Stage 1

0.67 (0.44 – 1.03)

0.49 (0.31 – 0.78)

0.54 (0.32 – 0.89)

Stage 2 and Stage 3

0.38 (0.25 – 0.59)

0.42 (0.26 – 0.67)

0.46 (0.28 – 0.78)

Reference

Reference

Reference

Age at Diagnosis:

Stage at Diagnosis:

Stage 4

p=0.16

p=0.01

Reference

Reference

$1,000 - $1,999

1.44 (1.05 – 1.98)

1.61 (1.15 – 2.25)

$2,000 – 2,999

1.54 (1.11 – 2.15)

1.24 (0.86 – 1.79)

$3,000 - $3,999

1.29 (0.93 – 1.81)

1.27 (0.88 – 1.82)

$4,000 - $4,999

1.43 (1.01 – 2.01)

1.65 (1.14 – 2.40)

≥$5,000

1.44 (1.07– 1.93)

1.59 (1.14 – 2.21)

Health Insurance:

p=0.51

p=0.0009

Uninsured

1.09 (0.65 – 1.83)

0.83 (0.45 – 1.54)

Medicaid

0.81 (0.61 – 1.08)

0.84 (0.59 – 1.19)

Medicare

0.99 (0.84 – 1.17)

0.64 (0.51 – 0.79)

Reference

Reference

Monthly Income:
<$1,000

Private insurance
Surgery:
Yes

p=0.001

p=0.0008

p=0.002

0.33 (0.17 – 0.64)

0.30 (0.15 – 0.61)

0.29 (0.13 – 0.62)
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Predictor

Unadjusted HR

Adjusted HR*

Adjusted HR**

(95% CI)

(95% CI)

(95% CI)

No

Reference

Reference

Reference

Radiation:

p=0.86

p=0.55

p=0.59

Yes

1.01 (0.88 – 1.17)

1.05 (0.90 – 1.21)

0.96 (0.81 – 1.13)

Reference

Reference

Reference

p<0.0001

p<0.0001

p<0.0001

Yes

0.33 (0.28 – 0.38)

0.30 (0.15 – 0.61)

0.27 (0.22 – 0.34)

No

Reference

Reference

Reference

No
Chemotherapy:

95% Confidence Interval (95% CI) of the hazards ratios are given in parentheses
*Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at
diagnosis, other types of treatment and stage at diagnosis
** Multivariate Cox Proportional Hazards Regression Model: Adjusting for age at
diagnosis, stage at diagnosis, other types of treatment, family’s monthly income and
health insurance
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Table 11: Spearman Correlation Coefficients
Variables

Appalachian
Region

Education
Attainment

Monthly
Income

Private
Insurance

Medicaid

Medicare

Appalachian
Region

1

-0.18

-0.19

-0.15

0.06

0.09

p<.0001

p<.0001

p<.0001

p=0.03

p=0.001

1

0.49

0.31

-0.14

-0.22

p<.0001

p<.0001

p<.0001

p<.0001

1

0.41

-0.28

-0.22

p<.0001

p<.0001

p<.0001

1

-0.39

-0.78

p<.0001

p<.0001

1

-0.17

Education
Attainment

-0.18
p<.0001

Monthly
Income

Private
insurance

Medicaid

Medicare

-0.19

0.49

p<.0001

p<.0001

-0.15

0.31

0.41

p<.0001

p<.0001

p<.0001

0.06

-0.14

-0.28

-0.39

p=0.03

p<.0001

p<.0001

p<.0001

0.09

-0.22

-0.22

-0.78

-0.17

p=0.001

p<.0001

p<.0001

p<.0001

p<.0001

p<.0001
1
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Table 12: Variance Inflation
Dependent Variable: Number of Days between Diagnosis Date and First Treatment
Variable

DF

Parameter Estimate

Standard Error

t Value

p value|

Variance Inflation

Intercept

1

22.03

2.40

9.19

<.0001

0

Appalachian Region

1

-2.59

1.36

-1.91

0.06

1.06

Education Attainment

1

0.34

0.50

0.68

0.49

1.34

Monthly Income

1

-0.18

0.41

-0.44

0.66

1.47

Health Insurance

1

0.22

0.89

0.25

0.80

1.25
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